How to Get Ozempic in New York: Telehealth Access

Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

In New York, getting Ozempic starts with a fact most articles skip: Ozempic is approved for type 2 diabetes, not for weight loss, so a New York prescriber evaluates you against that indication before anything is written. The Ozempic prescribing information lists three indications, all in adults with type 2 diabetes mellitus — improving glycemic control as an adjunct to diet and exercise, reducing the risk of major adverse cardiovascular events in those with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease. There is no weight-management indication and no BMI criterion anywhere in that label. Telehealth is a lawful and well-established way to have that evaluation in New York, and the state has some specific rules that shape how the visit and the prescription actually work.

What Telehealth Legally Means in New York

New York defines telehealth in statute rather than leaving it to custom. The New York State Department of Health describes it as the use of electronic information and communication technologies to deliver health care to patients at a distance, with the governing provisions at Public Health Law section 2999-cc and the associated regulations at Part 538 of Title 18. Recognized modalities include audio-only, audio-visual, remote patient monitoring and store-and-forward, and the covered activities span assessment, diagnosis, consultation, treatment, education and care management.

That framework matters for a metabolic consultation because it means an initial evaluation does not have to happen in a waiting room to be a real clinical encounter. It also means the encounter is held to the same professional standards as an in-person one — the modality changes the setting, not the duty of care or the licensure requirements that apply to the clinician seeing you.

New York's Electronic Prescribing Mandate

Here is the rule that surprises people who move to New York: prescribers in the state are mandated to prescribe electronically, and the mandate is not limited to controlled substances. The Department of Health states that practitioners are mandated to electronically prescribe both controlled and non-controlled substances, a requirement in force since March 27, 2016 under Title 10 NYCRR Part 80, with narrow exceptions permitting paper, oral or faxed prescriptions in defined circumstances.

Semaglutide is not a controlled substance, but the mandate covers it anyway. Practically, that means a New York telehealth prescription for a GLP-1 medication is transmitted directly from the prescriber's system to the pharmacy. You should not expect to be handed a paper script to shop around, and any service promising one is describing something that is not how New York works.

What the Evaluation Actually Covers

A responsible visit is not a form that ends in a prescription. Because Ozempic's indications are diabetes indications, the clinician is looking at glycemic history and laboratory evidence, current medications, and whether cardiovascular or renal disease is part of your picture — the second and third indications exist precisely because outcomes in those populations were studied.

Contraindications and warnings drive as much of the conversation as eligibility does. Semaglutide carries a boxed warning for risk of thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Labeled warnings and precautions include acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and pulmonary aspiration during general anesthesia or deep sedation. A telehealth visit that never raises any of these has not done the job.

Ozempic Versus the Rest of the Semaglutide Family

New Yorkers searching for Ozempic are often actually looking for weight management, and the distinction is worth getting right because it determines what can lawfully be prescribed for what. Wegovy is the semaglutide product approved for weight-related indications; Ozempic is the type 2 diabetes product. Semaglutide is also available in tablet form under a separate FDA-approved label covering Rybelsus and Ozempic tablets, again for type 2 diabetes and cardiovascular risk reduction.

Coverage follows the same logic. New York insurers and pharmacy benefit managers key prior authorization to the approved indication and to diagnosis coding, which is why a plan may cover one semaglutide product for one member and decline a different one for another. That is a benefit-design question your prescriber's office and your plan can answer; it is not something a telehealth intake form decides.

Where Compounded Semaglutide Fits — and Where It Does Not

Compounded semaglutide is not Ozempic, and it should never be described as a generic version of it. It is not an FDA-approved finished product, and as the FDA states, the agency does not review compounded versions of these drugs for safety, effectiveness, or quality. The FDA has also reported receiving adverse event reports after patients used compounded semaglutide, and has warned that some compounders may be using salt forms — semaglutide sodium and semaglutide acetate — which are different active ingredients than those used in the approved drugs.

The regulatory footing changed when the semaglutide shortage resolved: enforcement discretion for state-licensed 503A compounding pharmacies ended April 22, 2025, and for registered outsourcing facilities May 22, 2025. Compounded semaglutide today is dispensed by a licensed 503A pharmacy pursuant to a prescription written for an individual patient. If you pursue that route in New York, the questions that matter are which pharmacy is dispensing, under what state license, and which clinician is responsible for your care.

What a New York Telehealth Path Looks Like End to End

In practice the sequence is consistent: an intake that captures your history and medications, laboratory work where the clinician needs it, a synchronous or asynchronous review by a clinician authorized to practice with patients located in New York, an electronically transmitted prescription if treatment is appropriate, and scheduled follow-up. Follow-up is the part people underrate — dose decisions, tolerability and monitoring all happen there.

What no legitimate service will do is guarantee a prescription in advance. If a New York clinician determines that a GLP-1 medication is not appropriate for you, that determination is the service working correctly.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Can I get Ozempic through telehealth in New York?

Telehealth is a recognized way to be evaluated in New York, defined in Public Health Law section 2999-cc and covering audio-only, audio-visual, remote patient monitoring and store-and-forward modalities. Whether Ozempic specifically is appropriate depends on its approved indications, which are all in adults with type 2 diabetes. The clinician evaluating you decides; no service can promise a prescription before that evaluation happens.

Is Ozempic approved for weight loss in New York or anywhere else?

No. Ozempic's labeling lists three indications, all in adults with type 2 diabetes: improving glycemic control as an adjunct to diet and exercise, reducing major adverse cardiovascular events in those with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease. There is no weight-management indication and no BMI criterion in the label.

Why can't I get a paper prescription in New York?

New York requires practitioners to prescribe electronically for both controlled and non-controlled substances, a mandate in effect since March 27, 2016 under Title 10 NYCRR Part 80. Semaglutide is not a controlled substance, but the requirement applies to it regardless. Narrow exceptions permit paper, oral or faxed prescriptions in defined circumstances, but electronic transmission directly to a pharmacy is the norm.

What will a telehealth clinician ask about before prescribing semaglutide?

Expect questions covering glycemic and cardiovascular history, kidney function, current medications, and contraindications. Semaglutide carries a boxed warning for risk of thyroid C-cell tumors and is contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Labeled warnings also include pancreatitis, gallbladder disease, hypoglycemia, kidney injury from volume depletion, and severe gastrointestinal reactions.

Is compounded semaglutide the same as Ozempic?

No, and it is not a generic version of it. Compounded semaglutide is not an FDA-approved finished product, and the FDA states it does not review compounded versions of these drugs for safety, effectiveness, or quality. The agency has reported adverse events following use of compounded semaglutide and warned that some compounders used salt forms, which are different active ingredients than those in the approved products.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.